BPRG Bioprogress

RNS Number:5133C
BioProgress PLC
21 August 2007


For Immediate Release                                             21 August 2007

                                BioProgress plc

        Launch of XLWrap, a New Enabling Technology variant of TabWrap(TM)


London, UK, 21 August 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG), the specialty pharma and healthcare company, announces the launch
of XLWrap, a new modified release variant of TabWrap(TM).

XLWrap utilises the dry-coating of novel modified release tablet cores that
release active drugs at specific sites within the gastro-intestinal system. The
product has also been designed to deliver active pharmaceutical products with
sustained-release properties which aides patient compliance.

Currently, BioProgress has one product in development using the XLWrap enabling
technology in addition to its other TabWrap(TM) developments. This product is in
the specialist area of analgesia / anti-inflammatory medicine and will create an
enhanced generic version of a known niche product that is already on the market.
This specific product is due to be on the market in H2 2009, subject to the
usual regulatory approvals. The product will be marketed in certain territories
by BioProgress's own sales and marketing division Dexo, and will be partnered in
some of the larger territories such as the US and some EU markets with
specialist sales and marketing partners. BioProgress is currently entering into
profit share agreements with these partners as well as license and supply
agreements. These partners will be announced at a later date.

The current market for the product is estimated to be in excess of $300m
globally and BioProgress expects to achieve 10% of the market share within the
first 12 months of product launch.


Steve Martin, Chief Development Officer, BioProgress, said:

"BioProgress has been able to create a full innovative enabling platform using
TabWrap(TM). New advances in film design, interlinked with known tablet
technology, allows the Company to offer a single platform with multiple uses,
such as FastWrap(TM), EntWrap(TM) as well as XLWrap. Working with partners has
allowed us to accelerate and expand our program of product-based developments
and enhance our ability to commercialise products."


Richard Trevillion, Chief Executive Officer, BioProgress, said:

"Being able to launch a new technology with a specific product is a new step
forward in the evolution of the business. The application of our technology to
solve problems where traditional manufacturing techniques has failed is further
evidence of the uniqueness and strength of our business strategy."


For further information:

BioProgress Plc                                            + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                                    + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, The company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical products. The
business continues to develop innovative delivery mechanisms using its XGEL(TM)
polymer technology. For further information please go to www.bioprogress.com


Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company"s filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCOKKKBABKDQFB

Bioprogress (LSE:BPRG)
Historical Stock Chart
From Apr 2024 to May 2024

Bioprogress (LSE:BPRG)
Historical Stock Chart
From May 2023 to May 2024